{"title":"N-acetylcysteine: risk of false-low biochemistry test results due to interference with Siemens assays","public_updated_at":"2016-07-18T14:30:38Z","details":{"metadata":{"therapeutic_area":[],"bulk_published":false,"first_published_at":"2016-07-18T14:30:38Z","document_type":"drug_safety_update"},"change_history":[{"public_timestamp":"2016-07-18T14:30:38Z","note":"First published."}],"body":[{"content_type":"text/html","content":"\n<div class=\"call-to-action\">\n<h3 id=\"advice-for-healthcare-professionals\">Advice for healthcare professionals:</h3>\n\n<p>Professionals who are treating patients with N-acetylcysteine for paracetamol overdose should establish whether Siemens ADVIA Chemistry and Dimension/Dimension Vista instruments are used for laboratory testing of biochemistry and, if so, should:</p>\n\n<ul>\n  <li>\n    <p>do venipuncture and blood sampling before N-acetylcysteine administration; there is a risk of false low biochemistry test results and potential misinterpretation of physiological status if done during or immediately after administration</p>\n  </li>\n  <li>\n    <p>state if a patient is receiving N-acetylcysteine when requests for biochemistry tests (eg, cholesterol, uric acid, lactate) include any <a href=\"https://www.gov.uk/drug-device-alerts/siemens-advia-chemistry-and-dimension-dimension-vista-products-risk-of-false-low-results-due-to-interference-with-n-acetylcysteine#device-details\">affected assays</a> from these instruments</p>\n  </li>\n</ul>\n</div>\n\n<p>False low biochemistry test results may occur when testing samples drawn from patients receiving N-acetylcysteine for paracetamol overdose due to interference with the reaction assays of these Siemens instruments.</p>\n\n<p>Further information, including a full list of affected assays, can be found in a <a href=\"https://www.gov.uk/drug-device-alerts/siemens-advia-chemistry-and-dimension-dimension-vista-products-risk-of-false-low-results-due-to-interference-with-n-acetylcysteine\">medical device alert</a> sent 22 June 2016.</p>\n\n<p>Adverse incidents can be reported via: the <a rel=\"external\" href=\"https://yellowcard.mhra.gov.uk/\">Yellow Card Scheme</a> in England and Wales; the <a rel=\"external\" href=\"https://www.health-ni.gov.uk/articles/reporting-adverse-incident\">Northern Ireland Adverse Incident Centre</a>; or <a rel=\"external\" href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric\">Health Facilities Scotland</a>. </p>\n\n<p>Article citation: Drug Safety Update volume 9 issue 12, July 2016: 3.</p>\n"},{"content_type":"text/govspeak","content":"$CTA\r\n### Advice for healthcare professionals:\r\n\r\nProfessionals who are treating patients with N-acetylcysteine for paracetamol overdose should establish whether Siemens ADVIA Chemistry and Dimension/Dimension Vista instruments are used for laboratory testing of biochemistry and, if so, should:\r\n\r\n* do venipuncture and blood sampling before N-acetylcysteine administration; there is a risk of false low biochemistry test results and potential misinterpretation of physiological status if done during or immediately after administration\r\n\r\n* state if a patient is receiving N-acetylcysteine when requests for biochemistry tests (eg, cholesterol, uric acid, lactate) include any [affected assays](https://www.gov.uk/drug-device-alerts/siemens-advia-chemistry-and-dimension-dimension-vista-products-risk-of-false-low-results-due-to-interference-with-n-acetylcysteine#device-details) from these instruments\r\n\r\n$CTA \r\n\r\nFalse low biochemistry test results may occur when testing samples drawn from patients receiving N-acetylcysteine for paracetamol overdose due to interference with the reaction assays of these Siemens instruments.\r\n \r\nFurther information, including a full list of affected assays, can be found in a [medical device alert](https://www.gov.uk/drug-device-alerts/siemens-advia-chemistry-and-dimension-dimension-vista-products-risk-of-false-low-results-due-to-interference-with-n-acetylcysteine) sent 22 June 2016.\r\n\r\nAdverse incidents can be reported via: the [Yellow Card Scheme](https://yellowcard.mhra.gov.uk/) in England and Wales; the [Northern Ireland Adverse Incident Centre](https://www.health-ni.gov.uk/articles/reporting-adverse-incident); or [Health Facilities Scotland](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric). \r\n\r\nArticle citation: Drug Safety Update volume 9 issue 12, July 2016: 3.\r\n"}],"max_cache_time":10,"temporary_update_type":false},"routes":[{"path":"/drug-safety-update/n-acetylcysteine-risk-of-false-low-biochemistry-test-results-due-to-interference-with-siemens-assays","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","first_published_at":"2016-07-18T14:30:40Z","base_path":"/drug-safety-update/n-acetylcysteine-risk-of-false-low-biochemistry-test-results-due-to-interference-with-siemens-assays","description":"N-acetylcysteine may interfere with assays from Siemens ADVIA Chemistry and Dimension/Dimension Vista instruments, leading to false-low biochemistry test results.","content_id":"85ea4e65-184d-4e98-822f-2d98b053fecb","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-safety-update","base_path":"/drug-safety-update","content_id":"602be505-4cf4-4f8c-8bfc-7bc4b63a7f47","description":"Find drug safety updates issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Drug Safety Update","withdrawn":false,"details":{"document_noun":"update","filter":{"document_type":"drug_safety_update"},"format_name":"Drug Safety Update","show_summaries":true,"facets":[{"key":"therapeutic_area","name":"Therapeutic area","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthesia and intensive care","value":"anaesthesia-intensive-care"},{"label":"Cancer","value":"cancer"},{"label":"Cardiovascular disease and lipidology","value":"cardiovascular-disease-lipidology"},{"label":"Dentistry","value":"dentistry"},{"label":"Dermatology","value":"dermatology"},{"label":"Ear, nose and throat","value":"ear-nose-throat"},{"label":"Endocrinology, diabetology and metabolism","value":"endocrinology-diabetology-metabolism"},{"label":"GI, hepatology and pancreatic disorders","value":"gi-hepatology-pancreatic-disorders"},{"label":"Haematology","value":"haematology"},{"label":"Immunology and vaccination","value":"immunology-vaccination"},{"label":"Immunosuppression and transplantation","value":"immunosuppression-transplantation"},{"label":"Infectious disease","value":"infectious-disease"},{"label":"Neurology","value":"neurology"},{"label":"Nutrition and dietetics","value":"nutrition-dietetics"},{"label":"Obstetrics, gynaecology and fertility","value":"obstetrics-gynaecology-fertility"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Paediatrics and neonatology","value":"paediatrics-neonatology"},{"label":"Pain management and palliation","value":"pain-management-palliation"},{"label":"Psychiatry","value":"psychiatry"},{"label":"Radiology and imaging","value":"radiology-imaging"},{"label":"Respiratory disease and allergy","value":"respiratory-disease-allergy"},{"label":"Rheumatology","value":"rheumatology"},{"label":"Urology and nephrology","value":"urology-nephrology"}]},{"key":"first_published_at","name":"Published","short_name":"Published","type":"date","preposition":"published","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}],"available_translations":[{"title":"N-acetylcysteine: risk of false-low biochemistry test results due to interference with Siemens assays","public_updated_at":"2016-07-18T14:30:38Z","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","base_path":"/drug-safety-update/n-acetylcysteine-risk-of-false-low-biochemistry-test-results-due-to-interference-with-siemens-assays","description":"N-acetylcysteine may interfere with assays from Siemens ADVIA Chemistry and Dimension/Dimension Vista instruments, leading to false-low biochemistry test results.","api_path":"/api/content/drug-safety-update/n-acetylcysteine-risk-of-false-low-biochemistry-test-results-due-to-interference-with-siemens-assays","withdrawn":false,"content_id":"85ea4e65-184d-4e98-822f-2d98b053fecb","locale":"en"}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}